Last updated: February 22, 2026
What is NDC 70677-1272?
NDC 70677-1272 represents a specific pharmaceutical product, identified by the National Drug Code (NDC). The details associated with this code specify the drug name, formulation, dosage, manufacturer, and packaging. According to available data, NDC 70677-1272 corresponds to Amikacin Sulfate in Injection, 500 mg/2 mL produced by a contract manufacturing organization.
Market Overview
Patient Population
The drug targets bacterial infections requiring aminoglycosides. Key indications include complicated urinary tract infections, pneumonia, and sepsis. The patient population in the US is estimated at approximately 2 million cases annually, with 20-25% of these requiring aminoglycoside therapy [1].
Market Size
The injectable antibiotics segment, including aminoglycosides, had a market value of approximately USD 1.2 billion in 2022. Amikacin accounts for around 20% of this segment, equating to roughly USD 240 million. The injectable form remains standard for severe infections, despite rising use of oral antibiotics.
Competitive Landscape
Leading competitors include:
- Standard Amikacin (Brand & Generic): Multiple manufacturers, including Teva, Mylan, and Hikma.
- Alternative Injectables: Gentamicin, Tobramycin.
- Emerging Products: New antibiotics targeting multi-drug resistant bacteria, such as plazomicin.
Pricing is influenced by originator brands maintaining premium prices and generics offering substantial discounts.
Price Analysis
Current Pricing Data
The average wholesale price (AWP) for a 2 mL vial (500 mg) of amikacin sulfate ranges between USD 15-25. Contract prices and institutional contracts lower costs to USD 10-15 per vial.
| Pricing Source |
Price Range (USD) |
Notes |
| Wholesale AWP |
15-25 |
Retailer prices |
| Hospital Contracts |
10-15 |
Negotiated, volume-based |
| Medicaid Rebate Programs |
Lower than wholesale |
Reflects negotiated discounts |
Price Trends (2020-2023)
Prices have remained relatively stable after dropping following the rise of generics around 2015. No significant upward or downward trend appears, though recent manufacturing shortages for some generics have temporarily increased prices.
Future Price Projections
Projected price movements depend on generics market saturation, supply chain stability, and regulatory changes. Key factors include:
- Generic Market Competition: Increased competition could drive prices down to USD 8-12 per vial over the next two years.
- Supply Chain Disruptions: Manufacturing or raw material shortages could elevate prices temporarily to USD 20+ per vial.
- Regulatory Developments: Patent expirations for close competitors may influence pricing strategies, promoting price reductions for generics.
Price Prediction Model (2023–2027)
| Year |
Predicted Price Range (USD per vial) |
Contributing Factors |
| 2023 |
10-15 |
Stable generics supply, existing competition |
| 2024 |
9-14 |
Increased generic market entry, procurement efficiency |
| 2025 |
8-12 |
Market saturation, further price compression |
| 2026 |
8-11 |
Continued competition, potential manufacturing issues |
| 2027 |
9-13 |
Supply chain normalization, increased demand for severe infections |
Regulatory and Market Entry Barriers
- FDA Approval: As a generic product, NDC 70677-1272 requires FDA approval for manufacturing consistency.
- Market Entry Costs: Entry involves significant validation, quality control, and distribution setup.
- Pricing Pressures: Hospital and government procurement systems exert downward pressure.
Key Considerations for Stakeholders
- Companies should monitor supply chain reliability, especially raw material availability.
- Price sensitivity across institutional buyers may influence negotiated rates.
- Patent expirations and new entrants can accelerate price erosion.
Conclusion
NDC 70677-1272, as a generic amikacin sulfate injection, faces a mature market with limited growth projections. Price stability dominates current trends, with expected slight decreases driven by increased generic competition and procurement efficiencies. Short-term supply disruptions could temporarily inflate prices.
Key Takeaways
- The US market for injectable amikacin, including NDC 70677-1272, is valued at approximately USD 200-240 million annually.
- Current wholesale prices are between USD 10-15 per vial; retail prices range up to USD 25.
- Future prices are forecasted to decline gradually to USD 8-12 per vial by 2025-2026.
- Price fluctuations will depend on supply chain stability, generic market saturation, and regulatory factors.
- Entry barriers are high for new manufacturers due to FDA validation requirements and established competition.
FAQs
-
What is the primary use of NDC 70677-1272?
It is used to treat bacterial infections requiring aminoglycoside therapy, like complicated urinary tract infections and pneumonia.
-
Are prices for this drug declining?
Yes. Prices are expected to decrease gradually with increasing generic competition and procurement efficiencies.
-
What factors could cause prices to rise unexpectedly?
Supply chain disruptions, raw material shortages, or manufacturing issues could temporarily increase prices.
-
How does the competitive landscape influence pricing?
Multiple generics drive prices down; limited competition sustains higher prices.
-
What regulatory hurdles exist for new entrants?
Stringent FDA approval processes for manufacturing and quality control can delay market entry.
References
[1] Centers for Disease Control and Prevention. (2022). Antibiotic Use in the United States, 2022. CDC.
